Minnesota Congenital CMV Screening Program Shows Promise

A universal newborn screening and population-based surveillance program for congenital cytomegalovirus, which was ...

AUGUST 29, 2024

Assay Predicts Protection From CMV Events

There is a growing interest in assays that measure CMV-specific T-cell immunity, which may predict inherent ...

FEBRUARY 7, 2024

New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients

The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...

JUNE 6, 2023

Prevymis Gets Priority Review for New Indication Decision

Merck is seeking two new indications for Prevymis against cytomegalovirus in transplant patients.

FEBRUARY 17, 2023

Cytomegalovirus Vaccine in Final Stages of Development

A vaccine for cytomegalovirus (CMV), a common, yet not particularly well-known, virus linked to high rates of birth ...

JULY 11, 2022

FDA Approves Livtencity for Resistant Post-Transplant CMV

Although a rare disease overall, CMV is one of the most common infections experienced by both HSCT and SOT ...

NOVEMBER 24, 2021

Letermovir Prophylaxis Lowers CMV Risk in HCT Patients

The recently approved antiviral drug letermovir (Prevymis, Merck) significantly lowered the risk for clinically ...

APRIL 6, 2018

CMV Reactivation and Rx After Allo-HCT Pose Substantial Toll

Reactivation of CMV infection and preemptive therapy to prevent progression to CMV disease in allo-HCT recipients ...

MARCH 26, 2018

FDA Approves Prevymis to Prevent CMV Among Stem Cell Transplant Patients

The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...

NOVEMBER 9, 2017